Sintilimab, surufatinib, and temozolomide for advanced neuroendocrine cancer
Part of Cancer clinical trials.
This trial tests a combination of three drugs for people with advanced neuroendocrine carcinoma that has stopped responding to previous treatments. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of neuroendocrine cancer that has spread and cannot be removed with surgery.
- Your cancer has gotten worse or you had bad side effects from at least one prior treatment.
- You are between 18 and 75 years old.
- You have at least one tumor that can be measured on a scan.
- Your overall health is fairly good (able to do light work or be up and about).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new form of the chemotherapy drug irinotecan (called liposomal irinotecan) for people with advanced, aggressive neuroendocrine cancer that has not responded to at least one prior treatment. The goal is to see if this version of the drug works better or has fewer side effects.
This trial tests a combination of two targeted therapies (surufatinib and serplulimab) plus standard chemotherapy (platinum and etoposide) for people with a rare, aggressive type of cancer called neuroendocrine carcinoma that started outside the lung. The goal is to see if this new combination works better than chemotherapy alone.
This trial tests a combination of three drugs—chidamide (a protein regulator), sintilimab (an immune-boosting antibody), and bevacizumab (a growth-blocking antibody)—for patients with advanced neuroendocrine cancer that has spread or cannot be removed surgically and has progressed despite an initial treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests whether adding three medicines—sintilimab, IBI310, and surufatinib—can control advanced, high-grade neuroendocrine tumors (that cannot be removed by surgery or have spread). It may help if your cancer has grown despite standard treatment, or if you cannot take standard treatment due to side effects.
This trial tests a combination of two drugs (surufatinib and tislelizumab) for people with advanced lung cancer that has neuroendocrine markers. It may be an option if you haven't had certain prior treatments and your overall health is fairly good.
This trial tests a combination of targeted therapy (Surufatinib) and chemotherapy (Temozolomide and S-1) as a first treatment for advanced neuroendocrine tumors that have not been treated before. It aims to see if this drug combo is safe and effective.
Hear when a new Neuroendocrine Carcinomas (NEC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.